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ABSTRACT
Parkinson’s disease (PD) is a progressive neurodegenerative movement disorder that results
from the death of dopamine (DA) neurons. Over recent years, differentiated or undifferentiated
neural stem cells (NSCs) transplantation has been widely used as a means of cell replacement
therapy. However, compelling evidence has brought attention to the array of bioactive molecules
produced by stem cells, deﬁned as secretome. As described in the literature, other cell popula-
tions have a high-neurotrophic activity, but little is known about NSCs. Moreover, the exploration
of the stem cell secretome is only in its initial stages, particularly as applied to neurodegenera-
tive diseases. Thus, we have characterized the secretome of human neural progenitor cells
(hNPCs) through proteomic analysis and investigated its effects in a 6-hydroxidopamine (6-OHDA)
rat model of PD in comparison with undifferentiated hNPCs transplantation. Results revealed
that the injection of hNPCs secretome potentiated the histological recovery of DA neurons when
compared to the untreated group 6-OHDA and those transplanted with cells (hNPCs), thereby
supporting the functional motor amelioration of 6-OHDA PD animals. Additionally, hNPCs secre-
tome proteomic characterization has revealed that these cells have the capacity to secrete a
wide range of important molecules with neuroregulatory actions, which are most likely support
the effects observed. Overall, we have concluded that the use of hNPCs secretome partially
modulate DA neurons cell survival and ameliorate PD animals’ motor deﬁcits, disclosing
improved results when compared to cell transplantation approaches, indicating that the secre-
tome itself could represent a route for new therapeutic options for PD regenerative medicine.
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INTRODUCTION
Parkinson’s Disease (PD) is the second most
common chronic neurodegenerative disorder
in the elderly, and it is estimated to affect
about 1% of population over 60 years of age
[1, 2]. Clinically, PD is mainly characterized as a
motor disease. The diagnosis currently avail-
able depends on the identiﬁcation of cardinal
features, such as bradykinesia, muscular rigid-
ity, postural instability, and tremor that show a
nonlinear progression during the development
of the disease [3, 4]. These motor deﬁcits are
the result of the progressive loss of dopamine
(DA) neurons in the nigrostriatal pathway, par-
ticularly in the substantia nigra pars compacta
(SNpc), leading to the reduction of DA levels in
the striatum [3, 5, 6]. Despite pharmacological
advances, the current treatments do not
address the etiology of the disease and the
degenerative process is not avoided [7–10].
Therefore, new strategies based on the use of
stem cells, such as neural stem cells (NSCs),
have emerged as an alternative therapy for PD
[11, 12]. NSCs are multipotent stem cells iso-
lated from fetal and adult nervous system tis-
sues with the ability to self-renew and
differentiate into specialized functional neu-
rons and glial cells, making them an interesting
source of cells for neuronal repair after injury
or disease [12–14]. In fact, different reports
have already shown that the transplantation of
NSCs display therapeutic effects, such as the
capacity to protect and regenerate damaged
DA neurons, as well as the potential to
improve function in animal models of PD. For
instance, Harrower and colleagues [15] showed
a reliable long-term survival and integration of
transplanted NSCs in the striatum of rats
lesioned with 6-hydroxydopamine (6-OHDA).
According to the authors, an increase in dopa-
minergic (DAergic) ﬁber densities and synapse
formation was observed. Similarly, another
study demonstrated that the transplantation of
adult NSCs (expanded from the subependymal
zone) in the striatum of 6-OHDA-lesioned rats
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led to a functional recovery in these animals, a fact that was
positively correlated with DA transporter immunoreactivity re-
establishment in the host tissue [16]. Even though, growing
evidence suggests that the effects mediated by stem cell trans-
plants are not associated with the generation of new neurons
or glial cells [17, 18]. In fact, stem cells can secrete a wide
panel of bioactive agents (e.g., growth factors, cytokines, and
[micro]vesicles), which is deﬁned as secretome. The latter is
believed to be important in the modulation of several biologi-
cal processes, such as cell survival, proliferation and differenti-
ation, immunomodulation, antiapoptosis, and stimulation of
tissue adjacent cells [18–20]. Currently, there are no studies
regarding the application of NSCs secretome per se in animal
models of PD, nor its effect on DAergic neuronal cell popula-
tions. Nevertheless, some reports have suggested them as
neurotrophic-factor secreting cells [21]. Indeed, different stud-
ies showed that important neurotrophic factors, such as glial
cell line-derived neurotrophic factor (GDNF), brain-derived
neurotrophic factor (BDNF), stem cell factor (SCF), and insulin
growth factor (IGF), were found to be increased after NSCs
transplantation, thereby supporting NSCs mediated effects
[21–24]. Having this in mind, it would be interesting to further
explore the impact of the human progenitor cells (hNPCs)
secretome on the reversion of PD, when compared to more
conventional approaches like cell transplantation. Following
this, we analyzed the effects of hNPCs secretome on DA neu-
rons survival and motor function of a 6-OHDA-rat model of
PD, comparing it with the outputs obtained from animals’
transplanted undifferentiated hNPCs, and highlighted possible
new neuroregulatory molecules that mediate these actions.
MATERIALS AND METHODS
Primary Culture of hNPCs and Collection of the
Secretome
hNPCs cell culture was performed as previously described by
our group [25, 26], and according to the protocols and strict
ethical guidelines previously established and approved by the
Conjoint Health Research Ethics Board (CHREB, University of Cal-
gary, AB, ID: E-18786) [27–29]. Regarding conditioned media
(CM) collection, at passage 5 (P5), hNPCs were enzymatically
dissociated and plated into new tissue culture ﬂasks at a density
of 5,000 cells/cm2 for experiments, and 12,000 cells/cm2 for
proteomic procedures. After 14–20 days of growth in culture,
the cells were centrifuged and the supernatant was discarded.
Then, Neurobasal A medium (TermoFisher Scientiﬁc, 10888-022,
Waltham, MA, https://www.thermoﬁsher.com/pt/en/home.html)
supplemented with 1% kanamycin (TermoFisher Scientiﬁc,
15160-047) was added to the cells. After 24 h, this medium,
containing the factors secreted by hNPCs was collected, centri-
fuged at 250 g for 10 min to remove any cell debris, and then
stored at −80C until it was required for further experiments.
6-OHDA Lesions
All the experiments were done after the consent from the Por-
tuguese national authority for animal research, Direção Geral
de Alimentação e Veterinária (ID: DGAV28421, Lisbon, Portugal)
and Ethical Subcommittee in Life and Health Sciences (SECVS;
ID: SECVS-008/2013, University of Minho, Braga, Portugal), and
conducted in accordance with the local regulations on animal
care and experimentation (European Union Directive 2010/63/
EU). Eight-weeks-old Wistar-Han male rats (Charles River,
Barcelona, Spain, http://www.criver.com/) were housed in pairs,
in appropriate cages, under standard controlled conditions
(12-hour light/12-hour dark cycles; room temperature (RT) at
22–24C and 55% humidity; food and water ad libitum). For sur-
gical procedures, animals were anesthetized intraperitoneally
(i.p.) with ketamine (75 mg/kg) plus medetomidine (0.5 mg/kg),
placed on a stereotaxic frame (Stoelting, Wood Dale, IL, https://
www.stoeltingco.com/), and unilaterally injected using a
30-gauge needle Hamilton syringe (Hamilton, Bonaduz, Switzer-
land, https://www.hamiltoncompany.com/), with either vehicle
(0.2 mg/ml of ascorbic acid in 0.9% NaCl; sham group, n = 9) or
6-OHDA hydrochloride (Sigma, H4381, St. Louis, MO, http://
www.sigmaaldrich.com/portugal.html; 6-OHDA group, n = 15)
directly into the medial forebrain bundle (MFB; coordinates
related to Bregma: AP = −4.4 mm, ML = − 1.0 mm, DV = −7.8 mm
[30]) at a rate of 0.5 μl/min. Sham animals received 2 μl of
0.2 mg/ml of ascorbic acid (Sigma, A1968) in 0.9% NaCl and the
6-OHDA animals were injected with 2 μl of 6-OHDA hydrochlo-
ride (4 μg/μL) with 0.2 mg/ml of ascorbic acid in 0.9% NaCl. The
needle was left in place for 4 min after each injection to avoid
any backﬂow. The PD model with 6-OHDA injections into the
MFB was chosen due to their relevance to study anti-PD proper-
ties of novel therapies, such as cell replacement strategies or
the application of new drugs or cell-free therapeutic tools
(e.g., hNPCs secretome) [31–33]. Animals presenting more than
100 rotations in the apomorphine-induced turning behavior
(rotameter test) were consider having a complete lesion, as pre-
viously described by our group [34].
Surgical Treatment: Injection of hNPCs and hNPCs
Secretome
Five weeks after 6-OHDA injections, the animals received hNPCs
transplants or hNPCs secretome. After anesthesia administration,
animals were unilaterally injected, as described in previous sec-
tion, with either vehicle (Neurobasal A medium; 6-OHDA control
group, n = 5), sterile saline (sham group, n = 9), hNPCs (n = 5),
or hNPCs CM (n = 5) directly in the SNpc (coordinates related to
Bregma: AP = − 5.3 mm, ML = −1.8 mm, DV = −7.4 mm) and into
four striatum coordinates (coordinates related to Bregma:
AP = −1.3 mm, ML = 4.7 mm, DV = −4.5 mm, and − 4.0 mm;
AP = −0.4 mm, ML = 4.3 mm, DV = −4.5 mm, and 4.0 mm;
AP = 0.4 mm, ML = 3.1 mm, DV = −4.5 mm, and − 4.0 mm;
AP = 1.3 mm, ML = 2.7 mm; DV = −4.5 mm, and − 4.0 mm [30]).
6-OHDA-control group received 4 μl of Neurobasal A medium in
the SNpc and 2 μl in each coordinate of striatum at a rate of
0.5 μl/min. Cell transplanted groups received 200,000 cells in
SNpc and 50,000 cells in each coordinate of striatum. CM-
injected animals received 4 μl in the SNpc and 2 μl in each coor-
dinate of striatum at a rate of 0.5 μl/min. The needle was left in
place for 4 min after each injection to avoid any backﬂow.
Behavioral Assessment
Behavioral analysis was performed 3 weeks after 6-OHDA
injections for the PD model characterization and after treat-
ments at 1, 4, and 7 weeks following surgeries (Fig. 1). Motor
coordination and balance of the animals was evaluated using
the Rotarod test. The skilled paw reaching test (staircase test)
was used to assess the independent forelimb extension and
grasping skills. Finally, the extension of DA depletion was eval-
uated using the apomorphine-turning behavior test (rotameter
test). Understanding that apomorphine is a strong DA agonist,
© 2018 The Authors. STEM CELLS TRANSLATIONAL MEDICINE published by
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the continuous overstimulation of the DAergic system could
lead to an inadequate interpretation of the treatments impact
on the functional outcomes. Therefore, this test was only used
to select the animals that were truly injured upon 6-OHDA
lesions [35–37]. All behavioral tests were performed as previ-
ously described [30, 34].
TH Immunohistochemistry
After 13 weeks (including the development of the lesion and
consequent treatment) animals were sacriﬁced with sodium
pentobarbital (Eutasil, 60 mg/kg, i.p.; Ceva Saúde Animal, Algés,
Portugal, http://www.ceva.pt/) and transcardially perfused
using 4% paraformaldehyde (Merck, Lisbon, Portugal, http://
www.emdgroup.com/emd/index.html) in 0.01 M phosphate-
buffered saline (PBS). Four series of striatal and mesencephalon
coronal sections, 50 μm thick, were obtained using a vibratome
(Leica, VT1000S, Wetzlar, Germany, http://www.leicabiosystems.
com/) and processed as free-ﬂoating sections. Sections were
immersed for 20 min in 0.01 M PBS with 3% H2O2 for the inhi-
bition of endogenous peroxidase activity, and then permeabi-
lized for 10 min with 0.1% PBS-Triton (PBS-T). After this, the
sections were blocked for 2 h with 5% new born calf serum
(NBCS; ThermoFisher Scientiﬁc, 16010159, Waltham, MA) in
0.01 M PBS, and incubated overnight at 4C with rabbit tyro-
sine hydroxylase (TH) primary antibody (1:2,000; Merck Milli-
pore, AB152, Billerica, MA, http://www.merckmillipore.com/PT/
en?bd=1) diluted in 0.01 M PBS with 2% of NBCS (1:2,000).
Afterward, sections were sequential incubated during 30 min
at RT with a biotinylated secondary antibody (ThermoFisher
Scientiﬁc, TP-125-HL) and then with the streptavidine-
peroxidase solution (ThermoFisher Scientiﬁc, TP-125-HL). The
antigen visualization was performed using 25 mg of 3,30-
diaminobenzidine tetrahydrocloride (DAB; Sigma, D5905) in
50 ml of Tris-HCl 0.05 M (pH = 7.6) with 12.5 μl of H2O2. Sec-
tions were then mounted on superfrost slides and allowed to
dry in the dark. After 24 h, thionin counter-coloration was per-
formed and the sections were mounted using entellan (Merck
Millipore, 1079610500). To ensure a representative sampling
among the animals, four identical TH-labeled slices covering
the entire mesencephalon were chosen, including all the por-
tions of the SNpc. Using a brightﬁeld microscope (Olympus,
BX51, Tokyo, Japan, https://www.olympus-global.com/)
equipped with a digital camera (CANIMPEX Enterprises, Pixe-
LINK PL-A622, Halifax, NS, Canada), and with the help of Visio-
pharm software (Visiopharm, V2.12.3.0, Hørsholm, Denmark,
https://www.visiopharm.com/), the boundaries of SNpc area
were drawn. The delineation of this region was performed
through identiﬁcation of anatomic standard reference points
and with the help of the rat brain atlas [38]. Counting of total
TH-positive cells in the SNpc area was performed on both
hemispheres, and the data presented as the percentage (%) of
remaining TH-positive cells in the lesioned side compared to
the control side. All the analysis was performed under blind
conditions.
Striatal Fiber Density Measurement
TH-immunostained striatal sections (four sections per animal)
representing the coordinates of injection sites within the stria-
tum were photographed (×1 objective) using brightﬁeld illumi-
nation (Olympus, SZX16). All image analysis was completed
using the ImageJ software (National Institute of Health, v1.48,
Bethesda, MD, https://imagej.nih.gov/ij/). The optical density
of TH-positive ﬁbers was measured by densitometry, as previ-
ously described [30, 39]. The data are presented as percent-
ages of the contralateral striatum (intact side).
Immunostaining
Striatal and mesencephalon coronal sections (including SNpc)
were obtained and processed as described above. As ﬁrst
approach, sections were permeabilized with 0.3% PBS-T for
10 min. Then, the sections were blocked with a solution of
10% NCBS in 0.01 M PBS for 30 min. After that, the samples
were incubated overnight at 4C with the primary antibodies
namely, rabbit TH for DA neurons detection (1:1,000) and with
the mouse Human Nuclear Antigen (HNA, 1:200; Merck Milli-
pore, MAB1281) for hNPCs detection. Sections were afterward
incubated with the secondary antibodies: Alexa Fluor 594 goat
anti-mouse (1:1,000; ThermoFisher Scientiﬁc, A11005) and
Alexa Fluor 488 goat anti rabbit (1:1,000; ThermoFisher Scien-
tiﬁc, A11008) during 2 h at RT. All sections were incubated
with the nuclear counterstain 40,6-diamidino-2-phenylindole-
dihydrochloride (DAPI, 1:1,000; Sigma). Finally, the slides
were mounted in Immu-Mount (Thermo Scientiﬁc) and
observed at a confocal point-scanning microscope (Olympus,
FV1000).
Untargeted Mass Spectrometry Proteomic Analysis:
IDA and SWATH Acquisitions
Three biological replicates of hNPCs CM were ﬁrst concen-
trated (×100) using a 5 kDA cut-off concentrator (Vivaspin,
Figure 1. Experimental design. The PD model was induced by a 6-OHDA unilateral injection. Three weeks later, the animals were submit-
ted to a ﬁrst behavioral analysis (using the RotaRod, Staircase, and Rotameter tests) to characterize the model. After this, the animals
were treated with hNPCs or their secretome, which were injected in the SNpc and striatum. Then, behavior analysis was performed 1, 4,
and 7 weeks after treatments, using the RotaRod and Staircase tests. Finally, the animals were sacriﬁced to proceed with the histological
analysis. Abbreviations: 6-OHDA, 6-hydroxidopamine; hNPCs, human neural progenitor cells; SNpc, substantia nigra pars compacta.
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GE Healthcare, Little Chalfont, U.K., http://www3.gehealth-
care.com/en/global_gateway) by ultracentrifugation at
3,000 g during 45 min, as previously described [40]. After-
wards, the secreted proteins, were precipitated with Trichlor-
oacetic acid (TCA)—Acetone method [40] and the washed
pellets were resuspended in 40 μL ×2 Laemmli buffer
(BioRad, Hercules, CA, http://www.bio-rad.com/), aided by
ultrasonication and denaturation at 95C. Prior to protein
digestion, 10 μL of each replicate were used to create a
pooled sample for protein identiﬁcation. After denaturation,
samples were alkylated with acrylamide and subjected in gel
digestion by using the short-GeLC approach [41], and the
formed peptides were desalted using OMIX tips with C18 sta-
tionary phase (Agilent Technologies, Glostrup, Denmark,
http://www.agilent.com) before liquid chromatography-
tandem mass spectrometry (LC–MS/MS). Samples were then
analyzed on a Triple TOF 5600 System (Sciex, Framingham,
MA, https://sciex.com) in two phases: information-dependent
acquisition (IDA) of the pooled samples for library generation
and, Sequential Window Acquisition of All Theoretical Mass
Spectra (SWATH) acquisition of each individual sample to
performed protein identiﬁcation from the SWATH analysis
(detailed in Supporting Information Table S1). A speciﬁc
library of precursor masses and fragment ions was created by
combining all ﬁles from the IDA experiments, and used for
subsequent SWATH processing. Libraries were obtained using
ProteinPilot software (Sciex, v5.1) searching against a data-
base composed by Homo sapiens from SwissProt (release at
April 2016) and the sequence of the recombinant protein
malE-GFP. SWATH data processing was performed using
SWATH processing plug-in for PeakView (Sciex, v2.0.01).
Brieﬂy peptides were selected automatically from the library
and up to 15 peptides with up to 5 fragment ions were cho-
sen per protein identiﬁed below 5% local false discovery rate
(FDR) from ProteinPilot search. The chromatographic proﬁles
of the target fragment ions of those peptides were extracted
using an extracted-ion chromatogram (XIC) window of
4 minutes with 100 ppm XIC width. Proteins with at least
1 peptide with a FDR below 1% were considered for identiﬁ-
cation, and the ones that were just identiﬁed in a single bio-
logical replicate were not considered for analysis. The ﬁnal
list of proteins was used to functional characterize the hNPCs
CM by Gene Ontology and Pathways analysis using the Pro-
tein Analysis Through Evolutionary Relationships (PANTHER)
classiﬁcation system (http://pantherdb.org) [30].
Statistical Analysis
Data evaluation for animal behavior tests after 6-OHDA injec-
tions was performed using an independent Student’s t test
(RotaRod and Rotameter tests), and repeated measures
ANOVA if an evaluation along time was desired (Staircase
test). After treatments, the behavior and histological data
were analyzed using a one-way ANOVA to compare the mean
values for the four groups. If an evaluation along time was
required (RotaRod and Staircase tests), a mixed design facto-
rial ANOVA was performed. Multiple comparisons between
groups were accomplished through the Bonferroni statistical
test. The signiﬁcance value was set as p ≤ .05 and all the
results are presented as mean SEM (standard error of
the mean).
RESULTS
Phenotypic Characterization of 6-OHDA Lesions
To evaluate the functional integrity of the DAergic system,
after 6-OHDA injections (Fig. 2A), and therefore select the ani-
mals that were truly injured, the rotameter test was per-
formed at the end of behavior assessment (RotaRod and
staircase tests). Three weeks after the 6-OHDA injections, sta-
tistical analysis revealed differences in the number of
apomorphine-induced turning rotations in the 6-OHDA-
injected animals when compared to the sham group
(t(12) = 9.398, p < .0001; Fig. 2B). In addition, also the motor
performance of the animals was affected by the 6-OHDA injec-
tions. Regarding motor coordination and balance, measured
by the rotarod test, it was found to be impaired in animals
injected with 6-OHDA (t(19) = 4.034, p < .001; Fig. 2C). In the
staircase test, performed to assess the forelimb use and skilled
motor function, we also observed that the 6-OHDA-injected
animals were remarkably affected when compared to sham
animals (F1,22) = 48.727, p < .0001, η2partial = .689; Fig. 2D).
Injection of hNPCs CM Reduces the Motor Deﬁcits of
6-OHDA-Lesioned Animals
To address the effects of hNPCs transplantation and its CM
(i.e., secretome) in 6-OHDA-injected animals, the motor perfor-
mance was evaluated at 1, 4, and 7 weeks after treatment by
using the RotaRod and staircase tests, as previously described
[30]. Regarding motor coordination and balance (assessed by
the RotaRod test), the results showed a signiﬁcant effect for
the factor treatment (F(3,18) = 20.034, p ≤ .0001, η2partial = .770)
and for the factor time (weeks; F(3,54) = 2.824, p ≤ .05,
η2partial = 0.136), but no interaction between the factors
(F(9,54) = .751, p = .661). When we compared CM-injected ani-
mals with cells-transplanted animals, we observed a signiﬁcant
improvement of motor coordination performance promoted
by the hNPCs CM when compared to hNPCs-injected group
(p ≤ .05, Fig. 3A). Similar results were also observed in the
staircase test, used to assess the forelimb use and the ﬁne
motor coordination of the animals. Indeed, after CM injection,
statistical analysis revealed a signiﬁcant effect for the treat-
ment (F(3,20) = 21.740, p ≤ .0001, η2partial = .765) and for the
factor time (F(1.634,32.681) = 37.954, p ≤ .0001, η2partial = .665),
but no interaction between these two factors (F(4.902,32.681) =
0.672, p = .645). Comparing the animals injected with hNPCs
CM with the untreated group (6-OHDA), a post hoc analysis
revealed that the injection of hNPCs CM led to a signiﬁcant
improvement on the success rate of eaten pellets (p ≤ .05,
Fig. 3B). In addition, we were also able to observe that hNPCs
CM-injected animals presented a better motor performance
than those transplanted with hNPCs (p ≤ .05, Fig. 3B). Finally,
the hNPCs treatment did not lead to any motor improvements,
in both tests, when compared with the untreated group.
Injection of hNPCs CM Restores TH Deﬁcits
To analyze the effects of the 6-OHDA injections, as well as
the resulting treatments with hNPCs CM or hNPCs cell trans-
plantation, histological analyses for TH were performed.
From the results, we observed that there was a signiﬁcant
decrease of DA neurons after the injection of 6-OHDA into
the MFB (Fig. 4A–4D). After treatment, statistical analyses
© 2018 The Authors. STEM CELLS TRANSLATIONAL MEDICINE published by
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(F(3,23) = 109.868, p ≤ .0001, η2 = .943) demonstrated that
the injection of the hNPCs CM most likely play a role in the
DA neurons survival, leading to a signiﬁcant higher number
of TH-positive cells in the SNpc when compared with the
untreated group 6-OHDA (p < .05, Fig. 4E). The same obser-
vations were also found in the striatum, by assessing TH-
positive ﬁbers through densitometry analysis (Fig. 4F–4I).
Statistical analysis (F(3,20) = 91.258, p ≤ .0001, η2 = .942)
revealed that hNPCs CM was able to increase the TH expres-
sion levels when compared to the untreated group 6-OHDA
(p ≤ .05, Fig. 4J). To emphasize that, it was observed that
the treatment with hNPCs led to a small increase of TH-
positive cells in the SNpc, even though nonsubstantial, and
no differences were found in the striatum when compared
with the untreated group. Moreover, an immunostaining
against HNA was performed to identify the transplanted
hNPCs in both SNpc and striatum, as it is a speciﬁc marker
for human cells. Results showed that hNPCs were only found
in one animal in the SNpc (Supporting Information Fig. S1)
8 weeks post transplantation.
Figure 3. Behavioral characterization 1, 4, and 7 weeks after hNPCs transplantation and hNPCs CM (i.e., secretome) injection in the
SNpc and striatum. (A): Latency to fall was measured in the accelerating RotaRod test, demonstrating that the hNPCs CM-injected animals
had a statistical signiﬁcant improvement in their motor coordination when compared to the hNPCs-transplanted group (at 7 weeks after
injection). (B): The Staircase test also demonstrated a statistical signiﬁcant improvement of the forelimb coordination of the hNPCs CM-
injected animals when compared to both the untreated group 6-OHDA and the hNPCs-transplanted group (at 7 weeks after injection).
For the RotaRod test, n = 7 for sham group, n = 5 for 6-OHDA group, n = 5 for hNPCs transplanted group and n = 5 for NCPs CM-injected
animals. For the Staircase test, n = 9 for sham group, n = 5 for 6-OHDA group, n = 5 for hNPCs transplanted group and n = 5 for hNCPs
CM-injected animals. Data are presented as mean SEM. *p ≤ .05; Sham animals statistically different from all the other groups: #
p ≤ .0001. Abbreviations: 6-OHDA, 6-hydroxidopamine; hNPCs, human neural progenitor cells; hNPCs CM, human neural progenitor cells-
conditioned media; SNpc, substantia nigra pars compacta.
Figure 2. Behavioral characterization of 6-OHDA lesions. (A): The animals received unilateral injections of 6-OHDA directly in the MFB.
(B): Rotameter revealed that the animals injected with 6-OHDA exhibited an intense turning behavior when compared to sham group.
6-OHDA-injected animals also presented signiﬁcant impairment in motor coordination and balance (C) and in the paw-reaching test per-
formance (D). For the Rotameter test, n = 9 for sham group and n = 13 for 6-OHDA group. For the RotaRod test, n = 7 for sham group
and n = 14 for 6-OHDA group. For the Staircase test, n = 9 for sham group and n = 15 for 6-OHDA group. Data are presented as
mean SEM. ***p ≤ .001; ****p ≤ .0001. Abbreviations: 6-OHDA, 6-hydroxidopamine; MFB, medial forebrain bundle; sec, seconds; SNpc,
substantia nigra pars compacta; STR, striatum.
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hNPCs Secretome as a Source of Proteins with
Neuroregulatory Potential
To identify potential molecules in the hNPCs secretome that
could be involved in the prosperous responses of the
secretome-injected animals, we characterized the latter
through a nontargeted proteomic analysis based on a com-
bined mass spectrometry (MS) approach. From these results, it
was possible to identify 595 proteins (according to the Uni-
ProtKB/Swiss-Prot classiﬁcation; Supporting Information
Table S2) in the hNPCs secretome, from which 401 proteins
were common to the 3 replicates (Fig. 5A). From these, we
focused on speciﬁc proteins with actions in CNS, ﬁnding impor-
tant molecules in the context of PD. (Fig. 5B-5C; highlighted in
Table 1).
Discussion
In this study we used a well-deﬁned rat model of PD, induced
by a unilateral injection of 6-OHDA into the MFB [34]. This
model leads to the DA neurons degeneration mimicking the
appearance of the main motor deﬁcits associated with the PD
[34, 42]. As shown in the rotameter test (Fig. 2B), 6-OHDA-
injected animals displayed an intense turning behavior when
compared with the sham group, indicating a clear decline in
the functional integrity of the DAergic system. Moreover, we
veriﬁed that the motor function of these animals was also
affected, which is in agreement with previous reports [30, 43,
44]. In fact, the animals presented impairments in motor coor-
dination and balance, as assessed by the rotarod test (Fig. 2C),
and in the skilled motor function addressed by the staircase
test (Fig. 2D). Regarding the effects of hNPCs CM and hNPCs
on motor coordination and balance (assessed by the rotarod
test), we observed that the CM injection led to a signiﬁcant
improvement of the motor performance of the injected ani-
mals when compared with the hNPCs-transplanted group
(Fig. 3A). Similar outcomes were also seen in the staircase test,
in which we veriﬁed that the injection of hNPCs secretome
improved the success rate of eaten pellets in the CM-injected
animals when compared with the untreated group 6-OHDA
and to those transplanted with hNPCs (Fig. 3B). In addition to
this, we also observed that the administration of the hNPCs
secretome signiﬁcantly increase SNpc and striatal TH-positive
neurons and ﬁbers, respectively (Fig. 4), when compared with
the untreated group 6-OHDA. This improvement is most likely
mediating the positive motor functional gains that were
observed. Such evidences were not observed in hNPCs-
transplanted animals, probably due to the low rate survival of
cells upon transplantation, as we observed the presence of
them in just one animal (Supporting Information Fig. S1). In
fact, hNPCs have been described as a potential stem cell
Figure 4. Representative micrographs of brain slices stained for TH. Compared to the sham group (A, F), all the animals that were sub-
mitted to 6-OHDA injection presented a reduction of TH expression levels. However, animals injected with (D, I) hNPCs CM
(i.e., secretome) had signiﬁcantly more TH-positive staining when compared to the (B, G) 6-OHDA untreated group, both in (E) SNpc and
(J) striatum. Data are presented as mean SEM. *p ≤ .05; Sham animals statistically different from all the other groups: #, p ≤ .0001.
(Scale bar: 2000 μm). Abbreviations: 6-OHDA, 6-hydroxidopamine; hNPCs, human neural progenitor cells; hNPCs-CM, human neural pro-
genitor cells-conditioned media; SNpc, substantia nigra pars compacta; TH, tyrosine hydroxylase.
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source for the treatment of neurological disorders, including
PD. Thus, to further understand which molecules present in
the hNPCs secretome could be involved in the observed
results, a nontargeted proteomic approach by MS was per-
formed. In addition to the well-known neurotrophic factors
such as GDNF, BDNF, SCF, among others, our proteomic analy-
sis revealed the secretion of important neuroregulatory candi-
dates, such as 14-3-3 proteins, PEDF, Galectin-1, Cystatin C,
Clusterin, GDN, SEM7A, and Cadherin-2 (Table 1), with impor-
tant roles on the migration, differentiation, and neuroprotec-
tion mechanisms both in vitro and in vivo [45–55]. Concerning
(for instance) GDN, although its role in PD remains undiscov-
ered, studies have described this molecule as a modulator of
neuronal survival and neurite outgrowth [52]. From these,
PEDF was found to have important actions in the context of
PD [47, 56]. As stated by Falk and colleagues [57], PEDF is not
only neurotrophic but also neuroprotective in both 6-OHDA
and rotenone primary midbrain culture models of PD.
Evidence of neuroprotective action of this neuroregulatory
molecule has been linked to their capacity for incite the activa-
tion of nuclear factor NF-κB signaling cascade, allowing NF-κB
to act as a transcription factor that induces the expression of
genes that are crucial to neuronal protection and survival, such
as BDNF and GDNF [56]. Such evidence reinforces the impor-
tance of BDNF in PD, as it has been suggested that the
downregulation of BDNF expression in the SNpc can be one of
the initial steps at PD onset, which leads to an increased sensi-
tization of DA neurons [30, 58]. Still, Zheng and colleagues
[59] have also suggested that PEDF can decrease
mitochondria-derived reactive oxygen species generation, and
subsequently down-regulate VEGF-A expression, possibly
through the inhibition of the janus kinase 2/signal transducer
and activator of transcription 3 (JAK2/STAT3) activation. In
addition, Yasuda and colleagues [60] have recognized that
PEDF is a promoter of protective effects on various neuronal
populations, including DA neurons, indicating that an acute
damage induces a rise in PEDF levels in the CNS, thereby sup-
porting the hypothesis that PEDF acts as a natural PD neuro-
protective factor that has been correlated with motor
performance ameliorations. DJ-1, also identiﬁed in hNPCs
secretome, it is a multifunctional protein deeply linked to PD,
and the loss of its function is thought to result in the onset of
PD [61, 62]. DJ-1 is a stress sensor and its expression is
increased upon various stresses, including oxidative stress [61,
63, 64], modulating signaling pathways critical to cell survival
[65, 66]. Moreover, studies showed that the administration of
DJ-1 protein prevented DAergic cell death and restored loco-
motion in a 6-OHDA-rat model of PD, suggesting DJ-1 as a pos-
sible pharmaceutical target for PD [67, 68]. In addition to DJ-1,
we also found TrxR1, Prdx1, and SOD enzymes, which have
Figure 5. hNPCs secretome as a source of neuroregulatory molecules for PD. (A): Through combined MS analysis (IDA and STWAH acquisi-
tions.) it was possible to identiﬁed 595 proteins in the hNPCs CM, from which 401 proteins were common to the 3 replicates as shown in
the Venn Diagram. In accordance with Gene Ontology analysis of biological processes (B) and Protein Analysis Through Evolutionary Rela-
tionships (PANTHER) pathways (C), these proteins have neuroregulatory properties, n = 3. Abbreviations: hNPCs, human neural progenitor
cells; hNPCs-CM, human neural progenitor cells-conditioned media; IDA, information-dependent; MS, mass spectrometry; PD, Parkinson’s
disease; SWATH, Sequential Window Acquisition of All Theoretical Mass Spectra.
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been reported as important antioxidant agents and modula-
tors of oxidative stress [69–71]. For instance, Arodin and col-
leagues [72], using a Caenorhabditis elegans (C. elegans)
model, concluded that in the absence of TrxR1, DA neurons
were signiﬁcantly more sensitive to 6-OHDA, suggesting that
this molecule is important for neuronal survival in DA-induced
cell death. Regarding Prdx1, its overexpression in a DAergic
neuronal cell line has shown to revert the effects of 6-OHDA,
acting as ROS scavenger that led to DA neurons cell survival
and protection [73]. Similarly, SOD enzymes are often regarded
as the ﬁrst line of defense against ROS [70, 74]. Fibronectin for
instance, has also been described to exert neuroinﬂammatory
and neuroprotective roles [75]. Evidence showed that this gly-
coprotein could bind integrin and growth factor receptors
(such as IGF-1 receptor) to transactivate intracellular signaling
events, such as the PI3K/AKT pathway, leading to the increase
of growth factor-like neuroprotective actions [75]. Indeed,
accumulating evidence suggests that the normal functioning of
the PI3K/AKT pathway ensures the neuroprotective defense in
degenerating DA neurons, by limiting apoptosis, preventing
microglia activation and neuroinﬂammation, as well as pre-
venting ROS accumulation, thereby keeping oxidative stress
levels under control [76]. Interestingly, the results of a study
about the impact of Cadherin on PI3K/AKT activation sug-
gested that Cadherin-2 is indeed involved in the activation of
this signaling cascade in DA neurons, being triggered by the
glial cell line-derived neurotrophic factor (GDNF; of pivotal
importance for DA neuronal maintenance and development)
[54]. Finally, Dickkopf 3, was another molecule identiﬁed in
the secretome of hNPCs, which has been described as an
important modulator of DAergic neuronal differentiation
through the Wnt/β-catenin signaling pathway [77]. Still, as pre-
viously stated by Teixeira and colleagues [25], all the men-
tioned proteins have already been identiﬁed in different cell
secretomes by distinct proteomic-based techniques, support-
ing the results stated by our proteomic analysis. Hereupon,
our ﬁndings suggest that the modulation effect in DA neurons
triggered by hNPCs secretome could be related with the pres-
ence/expression of several secreted factors, as those discussed
above. This is in line with previous secretome studies from our
lab, which demonstrated similar effects in the same PD model,
as well as in the proteomic proﬁle, by using a different stem
cell population like human mesenchymal stem cells [30]. Nev-
ertheless, further research is required to carefully deﬁne which
molecules are imperative for the stem cells secretome-
mediated neuroprotective and regenerative properties. Eluci-
dation of the implicated molecular pathways is also a crucial
step toward improving our understanding of the secreted fac-
tor proﬁle and its clinical utility.
CONCLUSION
The ﬁndings of this study demonstrated that the injection of
hNPCs secretome enhanced the densities and ﬁbers of TH-
positive cells, a fact that probably explains the improved
behavioral performance of secretome-injected animals when
compared to the untreated group 6-OHDA and those trans-
planted with cells. The presence of important neuroregulatory
molecules within the secretome such as PEDF, DJ-1, Cadherin-
3, anti-oxidant proteins, among others, might play a role in
the observed outcomes. In fact, it has been described that
they are involved in different therapeutic mechanisms, includ-
ing DA neurons cell survival and protection, opening in this
way, new therapeutical opportunities for PD. Overall, our
results strongly suggest that the use of the secretome per se
may be considered as a possible tool for the treatment of PD,
as the secretome was able to better modulate DAergic neuro-
nal survival and animal behavior performance when compared
to cell transplantation.
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